Asset Details
Do you wish to reserve the book?
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Do you wish to request the book?
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
2013
Overview
Aims/hypothesis
We examined whether analysis of lipids by ultra-performance liquid chromatography (UPLC) coupled to MS allows the development of a laboratory test for non-alcoholic fatty-liver disease (NAFLD), and how a lipid-profile biomarker compares with the prediction of NAFLD and liver-fat content based on routinely available clinical and laboratory data.
Methods
We analysed the concentrations of molecular lipids by UPLC-MS in blood samples of 679 well-characterised individuals in whom liver-fat content was measured using proton magnetic resonance spectroscopy (
1
H-MRS) or liver biopsy. The participants were divided into biomarker-discovery (
n
= 287) and validation (
n
= 392) groups to build and validate the diagnostic models, respectively.
Results
Individuals with NAFLD had increased triacylglycerols with low carbon number and double-bond content while lysophosphatidylcholines and ether phospholipids were diminished in those with NAFLD. A serum-lipid signature comprising three molecular lipids (‘lipid triplet’) was developed to estimate the percentage of liver fat. It had a sensitivity of 69.1% and specificity of 73.8% when applied for diagnosis of NAFLD in the validation series. The usefulness of the lipid triplet was demonstrated in a weight-loss intervention study.
Conclusions/interpretation
The liver-fat-biomarker signature based on molecular lipids may provide a non-invasive tool to diagnose NAFLD, in addition to highlighting lipid molecular pathways involved in the disease.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Biological and medical sciences
/ Biopsy
/ Diabetes
/ Diabetes. Impaired glucose tolerance
/ Endocrine pancreas. Apud cells (diseases)
/ Etiopathogenesis. Screening. Investigations. Target tissue resistance
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Lipids
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
/ Medicine
